Phase 3 Major Depressive Disorder trials recruiting now
All Major Depressive Disorder trials, every phase
18
Phase 3 recruiting
Other phases for Major Depressive Disorder
Phase 3 Major Depressive Disorder trials
- A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Biomarker-guided rTMS for Treatment Resistant Depression
- Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder
- Efficacy of Statins Among Major Depressive Disorder
- INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
- Ketamine Augmentation of ECT in Treatment-Resistant Depression
- Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
- NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
- The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
Common questions
What does Phase 3 mean?
Is this list complete?
No. For the full record, search ClinicalTrials.gov.